Arcaini L, et al. - In this work, the long-term follow-up data and results of preplanned subgroup exploratory analyses from mantle cell lymphoma (MCL)-002 were assessed to compare lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. In patients with relapsed/refractory MCL, lenalidomide improved an overall progression-free survival vs single-agent investigator's choice therapy, irrespective of many demographic factors, disease characteristics and prior treatment history.